We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$172M 6.66%
2,530,131
– –
CELG
2
DELISTED
Celgene Corp
CELG
$170M 6.59%
1,366,605
-43,284
-3% -$5.18M
BIIB icon
3
Biogen
BIIB
$30.7B
$133M 5.14%
484,974
-52,376
-10% -$14.8M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$122B
$113M 4.38%
1,033,503
– –
AMGN icon
5
Amgen
AMGN
$209B
$112M 4.36%
684,824
+363,184
+113% +$60.3M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$96.5M 3.74%
795,905
– –
INCY icon
7
Incyte
INCY
$24.9B
$92.7M 3.59%
693,275
-187,186
-21% -$23.8M
JNJ icon
8
Johnson & Johnson
JNJ
$617B
$89M 3.45%
714,362
+271,150
+61% +$32.4M
MRK icon
9
Merck
MRK
$321B
$76.1M 2.95%
1,255,870
– –
AGN
10
DELISTED
Allergan plc
AGN
$74.2M 2.88%
310,610
-123,476
-28% -$28.8M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$77.4B
$72.7M 2.82%
187,666
– –
VTRS icon
12
Viatris
VTRS
$20.7B
$60.5M 2.34%
1,550,412
+414,860
+37% +$16.7M
ABT icon
13
Abbott
ABT
$183B
$51.2M 1.98%
1,152,520
-431,180
-27% -$18.6M
ILMN icon
14
Illumina
ILMN
$31B
$50.7M 1.97%
305,686
+52,222
+21% +$8.23M
UNH icon
15
UnitedHealth
UNH
$383B
$50.3M 1.95%
306,852
+60,932
+25% +$9.98M
MDT icon
16
Medtronic
MDT
$110B
$49.4M 1.91%
613,030
-10,000
-2% -$781K
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$16.2B
$48.1M 1.86%
331,411
– –
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.7B
$44.4M 1.72%
505,845
-66,800
-12% -$5.94M
LLY icon
19
Eli Lilly
LLY
$1.03T
$41.5M 1.61%
493,100
– –
SHPG
20
DELISTED
Shire pic
SHPG
$40.3M 1.56%
231,413
– –
PFE icon
21
Pfizer
PFE
$142B
$39.2M 1.52%
1,208,610
– –
TMO icon
22
Thermo Fisher Scientific
TMO
$214B
$35M 1.36%
228,020
+86,900
+62% +$13.3M
TEVA icon
23
Teva Pharmaceuticals
TEVA
$41.2B
$32.6M 1.26%
1,015,758
+226,800
+29% +$7.74M
CVS icon
24
CVS Health
CVS
$134B
$32.3M 1.25%
411,891
– –
HUM icon
25
Humana
HUM
$44B
$31.7M 1.23%
153,800
-11,000
-7% -$2.27M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.